FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1550-1559 November 18, 1993 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

Epithelial cancer of the ovary is the fifth most common malignant condition among women in the United States, with an annual incidence of 22,000 new cases¹. This disease predominantly affects postmenopausal women in their sixth decade, accounting for approximately 13,300 deaths each year and for over half of all deaths from genital cancer. The highly lethal nature of this tumor is related to the absence of symptoms in the majority of women with early stages of the disease. Seventy percent of women present with advanced disease in which the tumor has spread to the peritoneal surfaces of the upper . . . [Full Text of this Article]

Risk Factors for Ovarian Cancer

Clinical Presentation

Staging and Surgical Treatment

Postoperative Treatment

Limited Disease (Stages I and II)

Advanced Disease (Stages III and IV)

Methods to Obtain a Complete Pathological Response in Advanced Ovarian Cancer

Treatment Options for Persistent or Recurrent Disease

Secondary Debulking Surgery

Intraperitoneal Chemotherapy

Radiotherapy

Systemic, Non-Cross-Resistant Chemotherapy

Autologous Bone Marrow Transplantation

Summary and Future Directions

Source Information

From the Division of Medical Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston.

Address reprint requests to Dr. Cannistra at the Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115.

References

Related Letters:

Cancer of the Ovary
Lurain J., McKay M. J., Bull C. A., Collazos J., Embil J. M., Cannistra S. A.
Extract | Full Text  
N Engl J Med 1994; 330:1012-1014, Apr 7, 1994. Correspondence

This article has been cited by other articles:

• Helm, C. W. (2009). The Role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer. The Oncologist 14: 683-694 [Abstract] [Full Text]  
• ITANI, Y., HOSOKAWA, K., ITO, K., TAKEUCHI, S., TABATA, T., TSUBAMOTO, H., FUJITA, H., AKIYAMA, M., ADACHI, S. (2009). A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer. Anticancer Res 29: 1521-1526 [Abstract] [Full Text]  
• Johnatty, S. E., Beesley, J., Paul, J., Fereday, S., Spurdle, A. B., Webb, P. M., Byth, K., Marsh, S., McLeod, H., AOCS Study Group, , Harnett, P. R., Brown, R., deFazio, A., Chenevix-Trench, G. (2008). ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clin. Cancer Res. 14: 5594-5601 [Abstract] [Full Text]  
• Dimple, C., Nair, S. S., Rajhans, R., Pitcheswara, P. R., Liu, J., Balasenthil, S., Le, X.-F., Burow, M. E., Auersperg, N., Tekmal, R. R., Broaddus, R. R., Vadlamudi, R. K. (2008). Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis. Cancer Res. 68: 4902-4909 [Abstract] [Full Text]  
• Belotti, D., Calcagno, C., Garofalo, A., Caronia, D., Riccardi, E., Giavazzi, R., Taraboletti, G. (2008). Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. Mol Cancer Res 6: 525-534 [Abstract] [Full Text]  
• Chen, Y., Clark, S., Wong, T., Chen, Y., Chen, Y., Dennis, M. S., Luis, E., Zhong, F., Bheddah, S., Koeppen, H., Gogineni, A., Ross, S., Polakis, P., Mallet, W. (2007). Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models. Cancer Res. 67: 4924-4932 [Abstract] [Full Text]  
• Marca, A. L., Volpe, A. (2007). The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update 13: 265-273 [Abstract] [Full Text]  
• Lu, C., Bonome, T., Li, Y., Kamat, A. A., Han, L. Y., Schmandt, R., Coleman, R. L., Gershenson, D. M., Jaffe, R. B., Birrer, M. J., Sood, A. K. (2007). Gene Alterations Identified by Expression Profiling in Tumor-Associated Endothelial Cells from Invasive Ovarian Carcinoma. Cancer Res. 67: 1757-1768 [Abstract] [Full Text]  
• Pakkal, M V, Balogun, M (2006). Imaging of ovarian cancer. Imaging 18: 20-27 [Abstract] [Full Text]  
• Szotek, P. P., Pieretti-Vanmarcke, R., Masiakos, P. T., Dinulescu, D. M., Connolly, D., Foster, R., Dombkowski, D., Preffer, F., MacLaughlin, D. T., Donahoe, P. K. (2006). Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc. Natl. Acad. Sci. USA 103: 11154-11159 [Abstract] [Full Text]  
• Markman, M. (2006). "Therapeutic intent" in phase 1 oncology trials: a justifiable objective.. Arch Intern Med 166: 1446-1448 [Full Text]  
• Kim, M., Park, I.-Y., Lim, J., Kim, Y., Han, K. T., Chung, W. H., Han, K. (2006). Antitumor and Normal Cell Protective Effect of PKC412 in the Athymic Mouse Model of Ovarian Cancer. Annals of Clinical & Laboratory Science 36: 455-460 [Abstract] [Full Text]  
• Makarla, P. B., Saboorian, M. H., Ashfaq, R., Toyooka, K. O., Toyooka, S., Minna, J. D., Gazdar, A. F., Schorge, J. O. (2005). Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms. Clin. Cancer Res. 11: 5365-5369 [Abstract] [Full Text]  
• Thaker, P. H., Yazici, S., Nilsson, M. B., Yokoi, K., Tsan, R. Z., He, J., Kim, S.-J., Fidler, I. J., Sood, A. K. (2005). Antivascular Therapy for Orthotopic Human Ovarian Carcinoma through Blockade of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptors. Clin. Cancer Res. 11: 4923-4933 [Abstract] [Full Text]  
• Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., Bast, R. C., Stec, J., Iartchouk, N., Smith, D. I., Ross, J. S., Hoersch, S., Shridhar, V., Lillie, J., Kaufmann, S. H., Clark, E. A., Damokosh, A. I. (2005). Gene Expression Profiles Predict Early Relapse in Ovarian Cancer after Platinum-Paclitaxel Chemotherapy. Clin. Cancer Res. 11: 2149-2155 [Abstract] [Full Text]  
• Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., Libermann, Towia. A., Cannistra, S. A. (2004). Gene Expression Signature With Independent Prognostic Significance in Epithelial Ovarian Cancer. JCO 22: 4700-4710 [Abstract] [Full Text]  
• Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., Seino-Noda, H., Sakata, M., Motoyama, T., Kurachi, H., Testa, J. R., Tasaka, K., Murata, Y. (2004). Inhibition of Inhibitor of Nuclear Factor-{kappa}B Phosphorylation Increases the Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models. Clin. Cancer Res. 10: 7645-7654 [Abstract] [Full Text]  
• Sironi, S., Messa, C., Mangili, G., Zangheri, B., Aletti, G., Garavaglia, E., Vigano, R., Picchio, M., Taccagni, G., Maschio, A. D., Fazio, F. (2004). Integrated FDG PET/CT in Patients with Persistent Ovarian Cancer: Correlation with Histologic Findings. Radiology 233: 433-440 [Abstract] [Full Text]  
• de Caceres, I. I., Battagli, C., Esteller, M., Herman, J. G., Dulaimi, E., Edelson, M. I., Bergman, C., Ehya, H., Eisenberg, B. L., Cairns, P. (2004). Tumor Cell-Specific BRCA1 and RASSF1A Hypermethylation in Serum, Plasma, and Peritoneal Fluid from Ovarian Cancer Patients. Cancer Res. 64: 6476-6481 [Abstract] [Full Text]  
• Davies, E. J., Blackhall, F. H., Shanks, J. H., David, G., McGown, A. T., Swindell, R., Slade, R. J., Martin-Hirsch, P., Gallagher, J. T., Jayson, G. C. (2004). Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer. Clin. Cancer Res. 10: 5178-5186 [Abstract] [Full Text]  
• Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., Miyajima, A. (2004). Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion. J. Biol. Chem. 279: 9190-9198 [Abstract] [Full Text]  
• Apte, S. M., Fan, D., Killion, J. J., Fidler, I. J. (2004). Targeting the Platelet-Derived Growth Factor Receptor in Antivascular Therapy for Human Ovarian Carcinoma. Clin. Cancer Res. 10: 897-908 [Abstract] [Full Text]  
• Woodward, P. J., Hosseinzadeh, K., Saenger, J. S. (2004). From the Archives of the AFIP: Radiologic Staging of Ovarian Carcinoma with Pathologic Correlation. RadioGraphics 24: 225-246 [Abstract] [Full Text]  
• Kim, J.-H., Herlyn, D., Wong, K.-k., Park, D.-C., Schorge, J. O., Lu, K. H., Skates, S. J., Cramer, D. W., Berkowitz, R. S., Mok, S. C. (2003). Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer. Clin. Cancer Res. 9: 4782-4791 [Abstract] [Full Text]  
• Fracasso, P. M., Blessing, J. A., Morgan, M. A., Sood, A. K., Hoffman, J. S. (2003). Phase II Study of Oxaliplatin in Platinum-Resistant and Refractory Ovarian Cancer: A Gynecologic Group Study. JCO 21: 2856-2859 [Abstract] [Full Text]  
• Garofalo, A., Naumova, E., Manenti, L., Ghilardi, C., Ghisleni, G., Caniatti, M., Colombo, T., Cherrington, J. M., Scanziani, E., Nicoletti, M. I., Giavazzi, R. (2003). The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically. Clin. Cancer Res. 9: 3476-3485 [Abstract] [Full Text]  
• Schumer, S. T., Cannistra, S. A. (2003). Granulosa Cell Tumor of the Ovary. JCO 21: 1180-1189 [Abstract] [Full Text]  
• Bamberger, E S, Perrett, C W (2002). Angiogenesis in epithelian ovarian cancer. Mol. Pathol. 55: 348-359 [Abstract] [Full Text]  
• Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., Jaffe, R. B. (2002). Vascular Endothelial Growth Factor Immunoneutralization Plus Paclitaxel Markedly Reduces Tumor Burden and Ascites in Athymic Mouse Model of Ovarian Cancer. Am. J. Pathol. 161: 1917-1924 [Abstract] [Full Text]  
• Ahmed, N., Riley, C., Rice, G. E., Quinn, M. A., Baker, M. S. (2002). {alpha}v{beta}6 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer. J. Histochem. Cytochem. 50: 1371-1380 [Abstract] [Full Text]  
• Mabuchi, S., Ohmichi, M., Kimura, A., Hisamoto, K., Hayakawa, J., Nishio, Y., Adachi, K., Takahashi, K., Arimoto-Ishida, E., Nakatsuji, Y., Tasaka, K., Murata, Y. (2002). Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel. J. Biol. Chem. 277: 33490-33500 [Abstract] [Full Text]  
• Stephen, A. E., Pearsall, L. A., Christian, B. P., Donahoe, P. K., Vacanti, J. P., MacLaughlin, D. T. (2002). Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo. Clin. Cancer Res. 8: 2640-2646 [Abstract] [Full Text]  
• Huang, K.-C., Rao, P. H., Lau, C. C., Heard, E., Ng, S.-K., Brown, C., Mok, S. C., Berkowitz, R. S., Ng, S.-W. (2002). Relationship of XIST Expression and Responses of Ovarian Cancer to Chemotherapy. Molecular Cancer Therapeutics 1: 769-776 [Abstract] [Full Text]  
• Tedjarati, S., Baker, C. H., Apte, S., Huang, S., Wolf, J. K., Killion, J. J., Fidler, I. J. (2002). Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon {alpha} Combined with Paclitaxel. Clin. Cancer Res. 8: 2413-2422 [Abstract] [Full Text]  
• Cannistra, S. A. (2002). Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?. JCO 20: 1158-1160 [Full Text]  
• Hu, L., Hofmann, J., Lu, Y., Mills, G. B., Jaffe, R. B. (2002). Inhibition of Phosphatidylinositol 3'-Kinase Increases Efficacy of Paclitaxel in in Vitro and in Vivo Ovarian Cancer Models. Cancer Res. 62: 1087-1092 [Abstract] [Full Text]  
• Guichard, S., Montazeri, A., Chatelut, E., Hennebelle, I., Bugat, R., Canal, P. (2001). Schedule-dependent Activity of Topotecan in OVCAR-3 Ovarian Carcinoma Xenograft: Pharmacokinetic and Pharmacodynamic Evaluation. Clin. Cancer Res. 7: 3222-3228 [Abstract] [Full Text]  
• Gore, M., ten Bokkel Huinink, W., Carmichael, J., Gordon, A., Davidson, N., Coleman, R., Spaczynski, M., Heron, J.-F., Bolis, G., Malmstrom, H., Malfetano, J., Scarabelli, C., Vennin, P., Ross, G., Fields, S. Z. (2001). Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer. JCO 19: 1893-1900 [Abstract] [Full Text]  
• Braun, S., Schindlbeck, C., Hepp, F., Janni, W., Kentenich, C., Riethmuller, G., Pantel, K. (2001). Occult Tumor Cells in Bone Marrow of Patients With Locoregionally Restricted Ovarian Cancer Predict Early Distant Metastatic Relapse. JCO 19: 368-375 [Abstract] [Full Text]  
• Ismail, R. S., Baldwin, R. L., Fang, J., Browning, D., Karlan, B. Y., Gasson, J. C., Chang, D. D. (2000). Differential Gene Expression between Normal and Tumor-derived Ovarian Epithelial Cells. Cancer Res. 60: 6744-6749 [Abstract] [Full Text]  
• Yamamoto, K., Kikuchi, Y., Kudoh, K., Hirata, J., Kita, T., Nagata, I. (2000). Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma. Jpn J Clin Oncol 30: 446-449 [Abstract] [Full Text]  
• Hata, K., Takebayashi, Y., Akiba, S., Fujiwaki, R., Iida, K., Nakayama, K., Nakayama, S., Fukumoto, M., Miyazaki, K. (2000). Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 6: 867-872 [Abstract] [Full Text]  
• Tempany, C. M. C., Zou, K. H., Silverman, S. G., Brown, D. L., Kurtz, A. B., McNeil, B. J. (2000). Staging of Advanced Ovarian Cancer: Comparison of Imaging Modalities-Report from the Radiological Diagnostic Oncology Group. Radiology 215: 761-767 [Abstract] [Full Text]  
• Piccart, M. J., Green, J. A., Lacave, A. J., Reed, N., Vergote, I., Benedetti-Panici, P., Bonetti, A., Kristeller-Tome, V., Fernandez, C. M., Curran, D., Van Glabbeke, M., Lacombe, D., Pinel, M.-C., Pecorelli, S. (2000). Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group. JCO 18: 1193-1202 [Abstract] [Full Text]  
• Chan, W.-Y., Cheung, K.-K., Schorge, J. O., Huang, L.-W., Welch, W. R., Bell, D. A., Berkowitz, R. S., Mok, S. C. (2000). Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. Am. J. Pathol. 156: 409-417 [Abstract] [Full Text]  
• Markman, M., Bookman, M. A. (2000). Second-Line Treatment of Ovarian Cancer. The Oncologist 5: 26-35 [Abstract] [Full Text]  
• Horton, H. M., Dorigo, O., Hernandez, P., Anderson, D., Berek, J. S., Parker, S. E. (1999). IL-2 Plasmid Therapy of Murine Ovarian Carcinoma Inhibits the Growth of Tumor Ascites and Alters Its Cytokine Profile. J. Immunol. 163: 6378-6385 [Abstract] [Full Text]  
• Gamallo, C., Palacios, J., Moreno, G., Calvo de Mora, J., Suarez, A., Armas, A. (1999). {beta}-Catenin Expression Pattern in Stage I and II Ovarian Carcinomas : Relationship with {beta}-Catenin Gene Mutations,Clinicopathological Features, and Clinical Outcome. Am. J. Pathol. 155: 527-536 [Abstract] [Full Text]  
• Penson, R. T., Seiden, M. V. (1999). Progress in Gynecologic Oncology. The Oncologist 4: 293-298 [Full Text]  
• Barbieri, F., Cagnoli, M., Ragni, N., Foglia, G., Bruzzo, C., Pedulla, F., Alama, A. (1999). Increased Cyclin D1 Expression Is Associated with Features of Malignancy and Disease Recurrence in Ovarian Tumors. Clin. Cancer Res. 5: 1837-1842 [Abstract] [Full Text]  
• Tai, Y.-T., Strobel, T., Kufe, D., Cannistra, S. A. (1999). In Vivo Cytotoxicity of Ovarian Cancer Cells through Tumor-selective Expression of the BAX Gene. Cancer Res. 59: 2121-2126 [Abstract] [Full Text]  
• Markman, M., Kennedy, A., Webster, K., Elson, P., Peterson, G., Kulp, B., Belinson, J. (1999). Clinical Features of Hypersensitivity Reactions to Carboplatin. JCO 17: 1141-1141 [Abstract] [Full Text]  
• Vikhanskaya, F., Colella, G., Valenti, M., Parodi, S., D'Incalci, M., Broggini, M. (1999). Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage. Clin. Cancer Res. 5: 937-941 [Abstract] [Full Text]  
• Cannistra, S. A. (1999). Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited. JCO 17: 741-741 [Full Text]  
• Makatsoris, T., Seiden, M. V. (1997). High-Dose Therapy for Ovarian Carcinoma. The Oncologist 2: 330-339 [Abstract] [Full Text]  
• Strobel, T., Swanson, L., Korsmeyer, S., Cannistra, S. A. (1996). BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93: 14094-14099 [Abstract] [Full Text]  
• Lurain, J., McKay, M. J., Bull, C. A., Collazos, J., Embil, J. M., Cannistra, S. A. (1994). Cancer of the Ovary. NEJM 330: 1012-1014 [Full Text]  
• Stephen, A. E., Masiakos, P. T., Segev, D. L., Vacanti, J. P., Donahoe, P. K., MacLaughlin, D. T. (2001). Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo. Proc. Natl. Acad. Sci. USA 98: 3214-3219 [Abstract] [Full Text]